Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 20

1.

Dysregulation of the mTOR pathway mediates impairment of synaptic plasticity in a mouse model of Alzheimer's disease.

Ma T, Hoeffer CA, Capetillo-Zarate E, Yu F, Wong H, Lin MT, Tampellini D, Klann E, Blitzer RD, Gouras GK.

PLoS One. 2010 Sep 20;5(9). pii: e12845. doi: 10.1371/journal.pone.0012845.

2.

Synaptic changes in Alzheimer's disease and its models.

Pozueta J, Lefort R, Shelanski ML.

Neuroscience. 2013 Oct 22;251:51-65. doi: 10.1016/j.neuroscience.2012.05.050. Epub 2012 Jun 9. Review.

PMID:
22687952
3.

Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior.

Selkoe DJ.

Behav Brain Res. 2008 Sep 1;192(1):106-13. doi: 10.1016/j.bbr.2008.02.016. Epub 2008 Feb 17. Review.

4.

[Effects of amyloid β-protein on hippocampal long-term potentiation].

Zhang JF, Yang D, Qi JS.

Sheng Li Xue Bao. 2010 Dec 25;62(6):479-88. Review. Chinese.

5.

Synaptic plasticity disruption by amyloid beta protein: modulation by potential Alzheimer's disease modifying therapies.

Rowan MJ, Klyubin I, Wang Q, Anwyl R.

Biochem Soc Trans. 2005 Aug;33(Pt 4):563-7. Review.

PMID:
16042545
6.
7.
8.

Synaptic plasticity in animal models of early Alzheimer's disease.

Rowan MJ, Klyubin I, Cullen WK, Anwyl R.

Philos Trans R Soc Lond B Biol Sci. 2003 Apr 29;358(1432):821-8. Review.

9.

Involvement of 'stress-response' kinase pathways in Alzheimer's disease progression.

Mairet-Coello G, Polleux F.

Curr Opin Neurobiol. 2014 Aug;27:110-7. doi: 10.1016/j.conb.2014.03.011. Epub 2014 Apr 5. Review.

10.

Mammalian target of rapamycin: a valid therapeutic target through the autophagy pathway for Alzheimer's disease?

Cai Z, Zhao B, Li K, Zhang L, Li C, Quazi SH, Tan Y.

J Neurosci Res. 2012 Jun;90(6):1105-18. doi: 10.1002/jnr.23011. Epub 2012 Feb 16. Review.

PMID:
22344941
11.

Targeting the mTOR signaling network for Alzheimer's disease therapy.

Wang C, Yu JT, Miao D, Wu ZC, Tan MS, Tan L.

Mol Neurobiol. 2014 Feb;49(1):120-35. doi: 10.1007/s12035-013-8505-8. Epub 2013 Jul 14. Review.

PMID:
23853042
12.

MAPK, beta-amyloid and synaptic dysfunction: the role of RAGE.

Origlia N, Arancio O, Domenici L, Yan SS.

Expert Rev Neurother. 2009 Nov;9(11):1635-45. doi: 10.1586/ern.09.107. Review.

PMID:
19903023
13.

Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes.

Medina M, Avila J.

Expert Rev Neurother. 2013 May;13(5):495-503. doi: 10.1586/ern.13.39. Review.

PMID:
23621307
14.

Plasticity and mTOR: towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disorders.

Gipson TT, Johnston MV.

Neural Plast. 2012;2012:486402. doi: 10.1155/2012/486402. Epub 2012 Apr 30. Review.

15.

mTOR signaling: at the crossroads of plasticity, memory and disease.

Hoeffer CA, Klann E.

Trends Neurosci. 2010 Feb;33(2):67-75. doi: 10.1016/j.tins.2009.11.003. Epub 2009 Dec 4. Review.

16.

Signaling pathway cross talk in Alzheimer's disease.

Godoy JA, Rios JA, Zolezzi JM, Braidy N, Inestrosa NC.

Cell Commun Signal. 2014 Mar 28;12:23. doi: 10.1186/1478-811X-12-23. Review.

17.

The role of mTOR signaling in Alzheimer disease.

Oddo S.

Front Biosci (Schol Ed). 2012 Jan 1;4:941-52. Review.

18.

Targeting synaptic dysfunction in Alzheimer's disease therapy.

Nisticò R, Pignatelli M, Piccinin S, Mercuri NB, Collingridge G.

Mol Neurobiol. 2012 Dec;46(3):572-87. doi: 10.1007/s12035-012-8324-3. Epub 2012 Aug 23. Review.

PMID:
22914888
19.

Potential of GPCRs to modulate MAPK and mTOR pathways in Alzheimer's disease.

Franco R, Martínez-Pinilla E, Navarro G, Zamarbide M.

Prog Neurobiol. 2017 Feb - Mar;149-150:21-38. doi: 10.1016/j.pneurobio.2017.01.004. Epub 2017 Feb 9. Review.

PMID:
28189739
20.

TOR on the brain.

Garelick MG, Kennedy BK.

Exp Gerontol. 2011 Feb-Mar;46(2-3):155-63. doi: 10.1016/j.exger.2010.08.030. Epub 2010 Sep 16. Review.

Supplemental Content

Support Center